Alluvi, previously BI 4744, offers a notable development in obesity care. This dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide receptors demonstrates compelling efficacy in clinical https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/